Clinical Manual For Treatment Of Schizophrenia

The Clinical Manual for the Treatment of Schizophrenia provides a wide-ranging, empirically based review of assessment and treatment issues in schizophrenia, offered from a multicultural and supremely patient-centered perspective. The following features reflect the care taken in developing this manual, as well as the inclusive nature of the contents: The initial chapter offers a thorough introduction to the disease -- its history, etiology, epidemiology, risk factors, and social aspects -- seen through the lens of a case study. The chapter ends with an overview of the diagnostic process, allowing the reader to place what follows into context. The basic science underlying schizophrenia is explained next, with coverage of biological markers; brain structure, function, and cytology; the dopamine and glutamate hypotheses; and the neurodevelopmental model of the disease. The chapter on clinical assessment focuses on making the differential diagnosis according to established criteria, with emphasis on a person-oriented approach that takes into account early trauma, stressful events, and the subjective well-being of the patient. Subsequent chapters explore cognition, comorbidity, substance abuse, and treatment-resistant symptoms in schizophrenia. Finally, chapters on the pharmacological and psychosocial treatment of schizophrenia compare and contrast these approaches, ensuring that the reader is completely up-to-date and knowledgeable about available treatment options. Clinicians who work with schizophrenic patients in a variety of settings -- from private practice to emergency departments -- will benefit from the scholarship and experience of this manual's astute and insightful authors.

Clinical Manual for the Treatment of Schizophrenia provides a uniquely multicultural and supremely patient-centered perspective on schizophrenia's core symptoms, its psychosocial effects, and its psychopharmacological and psychotherapeutic management.

Despite growing awareness in the psychiatric community of the multifaceted medical needs of the severely mentally ill, statistics show that as much as 60% of all schizophrenia patients die prematurely from nonpsychiatric medical conditions -- in part because many physicians have not yet recognized how to properly treat common diseases and illnesses within this complex patient population. Medical Illness and Schizophrenia, Second Edition, is the only clinical guide to focus exclusively on the treatment of common medical comorbidities among patients with schizophrenia. Like its best-selling predecessor, the book compiles the latest research and clinical information on integrating medical and psychiatric care for the schizophrenia patient. Twenty-eight physicians and psychiatrists, including editors Jonathan M. Meyer, M.D., and Henry A. Nasrallah, M.D., lend their expertise to this new, expanded edition. In fifteen chapters, this volume covers a wide range of common medical problems -- from metabolic and heart conditions, such as cardiovascular disease, hyperlipidemia, obesity and diabetes, to substance abuse and smoking. Each chapter concludes with "Key Clinical Points" that summarize important concepts and ensure reader retention. Additionally, the second edition includes new chapters that touch on some of the most complex clinical issues in the field of schizophrenia treatment today: Recent trends in the integration of medical and mental healthcare Behavioral treatments for weight loss in persons with schizophrenia Treatment of sexual dysfunction among persons treated for schizophrenia Health outcomes of schizophrenia treatment in children and adolescents Health outcomes of schizophrenia treatment during pregnancy and breastfeeding As the only clinical text of its kind, Medical Illness and Schizophrenia, Second Edition, is an invaluable resource for psychiatrists, nurses, healthcare professionals, and psychiatric and clinical residents. The goal of this text has always been to help clinicians recognize schizophrenia as both a brain disorder and a systemic disease with multiple manifestations that go beyond the obvious psychiatric symptoms -- and thus take a broader approach to treatment of schizophrenia. This new edition is a comprehensive, practical manual that serves as a reference for the medical management of seriously mentally ill patients across the age spectrum in both inpatient and outpatient settings.

Dr. Torrey has now updated and expanded all sections of this classic work, especially those chapters dealing with treatment and rehabilitation. He also focuses on the lack of adequate funding for research and treatment, and offers advice to families on how to improve services for those with schizophrenia. Illustrated.

This innovative book is a treatment manual, describing the use of cognitive behaviour therapy (CBT) with schizophrenia and providing details of how this can be put into practice, safely and effectively, in a variety of settings. The book is essentially practical and is clearly written for a range of mental health care professionals.

The second edition of this popular volume has been thoroughly updated, offering new information on the advances in research and management since the publication of the first edition a decade ago.

According to David Satcher, M.D., Ph.D., the 16th U.S. Surgeon General, we know a great deal more about treating mental illnesses than about preventing them and promoting mental health. In his foreword to Clinical Manual of Prevention in Mental Health, Dr. Satcher applauds this guide as timely and vital, as it provides new and emerging research on the importance of prevention in mental health. Clinical Manual of Prevention in Mental Health was conceived through discussions within the Prevention Committee of the Group for the Advancement of Psychiatry (GAP), and features contributions from 30 highly regarded clinicians and researchers who are experienced in the treatment and prevention of specific types of mental illnesses. Clinical Manual of Prevention in Mental Health will help you move toward widespread adoption of mental illness prevention in your own practice setting. This important new reference provides practical suggestions to help you work toward preventing, or implementing preventive measures in the treatment of Mood disorders Anxiety disorders Schizophrenia Substance use disorders Suicidality Family violence Conduct disorder and other adolescent disorders Late-life depression, dementia, and mild cognitive impairment Physical illnesses in psychiatric settings Cigarette smoking Compared with other areas of medicine, such as the prevention of infectious disease, our understanding of the prevention of mental illnesses remains in a relatively nascent state, especially in terms of how prevention can be incorporated into routine clinical practice. The authors of the various chapters have endeavored to balance reviewing the available research knowledge with providing guidance for practicing clinicians on how such knowledge can be incorporated into everyday practice. Clinical Manual of Prevention in Mental Health urges clinicians everywhere to inquire about risk factors and protective factors in patients' lives in addition to focusing on the presenting problem. It is the authors' intent to provide mental health professionals with the knowledge and practical applications necessary to be prevention-minded in all of their interactions with patients, families, and the community.

Research on the nature and treatment of schizophrenia has undergone a revival and metamorphosis in the last decade. For a long while, the field had been moribund, weighed down by an unreliable diagnostic system, pessi mism about the possibility of new discoveries, and a dearth of research funds. A number of factors have seemingly coalesced to change this situa tion, with the result that the field is now alive with excitement and optimism. Four factors seem to have played important roles in the resurgence of interest. First, prior to the publication of DSM-III in 1980 there was no reliable diagnostic system for the disorder. Previous definitions were overly general and imprecise. Consequently, the label "schizophrenia" applied to a very heterogeneous group of severely disturhed patients. It was rarely clear whether two investigators had studied comparable samples, making it im possible to determine if (flew findings were generalizahle or if failures to replicate were due to the unreliahility of the results or the fact that the investigators had studied different disorders. DSM-III has not totally re solved this problem, but it has allowed scientists to reliably identify a much more homogeneous group. As a result, it is now possible to integrate the results of different studies, making it much more likely that we can make important advances. The second important factor was the development of new technologies that promised to help uncover the nature and etiology of the disorder.